Baptist medical center
Christus santa rosa childrens hospital
Methodist willowbrook hospital
North central baptist hospital
Northeast baptist hospital
Southeast baptist hospital
St lukes baptist hospital
University health system
UT Medicine San Antonio
Christus Santa Rosa Hospital
Ctrc@Ut Health Science Ctr.
Veterans Administration Hospital
Christus Santa Rosa
Survivin: key regulator of mitosis and apoptosis and novel target for cancer therapeutics.
Clin. Cancer Res., Aug;14(16):5000-5 (2008)
Autophagy inhibition enhances vorinostat-induced apoptosis via ubiquitinated protein accumulation.
J. Cell. Mol. Med., Oct;14(10):2448-59 (2010)
Targeting sarcomas: novel biological agents and future perspectives.
Curr Drug Targets., Oct;10(10):937-49 (2009)
Vorinostat enhances the activity of temsirolimus in renal cell carcinoma through suppression of survivin levels.
Clin. Cancer Res., Jan;16(1):141-53 (2010)
Clinical activity of mammalian target of rapamycin inhibitors in solid tumors.
Target Oncol., Jun;6(2):69-94 (2011)
The molecular target of rapamycin (mTOR) as a therapeutic target against cancer.
Cancer Biol. Ther., 2(4 Suppl 1):S169-77 (2003)
Development of rationally designed, target-based agents for the treatment of advanced colorectal cancer.
Clin Colorectal Cancer., Jul;4(2):107-23 (2004)
A phase II, pharmacokinetic, and biologic study of semaxanib and thalidomide in patients with metastatic melanoma.
Cancer Chemother. Pharmacol., Feb;59(2):165-74 (2007)
Phase I, pharmacokinetic, and biological study of erlotinib in combination with paclitaxel and carboplatin in patients with advanced solid tumors.
Clin. Cancer Res., Dec;12(24):7406-13 (2006)
The role of mTOR inhibitors for treatment of sarcomas.
Curr Oncol Rep., Jul;9(4):316-22 (2007)
Heat shock proteins: a potential anticancer target.
Curr Drug Targets., Dec;12(14):2001-8 (2011)
Phase I study of cetuximab, erlotinib, and bevacizumab in patients with advanced solid tumors.
Cancer Chemother. Pharmacol., May;63(6):1065-71 (2009)
Targeting the mTOR pathway using deforolimus in cancer therapy.
Future Oncol., Apr;5(3):291-303 (2009)
Mammalian target of rapamycin: a new molecular target for breast cancer.
Clin. Breast Cancer., Jun;4(2):126-37 (2003)
Phase I trial of the novel mammalian target of rapamycin inhibitor deforolimus (AP23573; MK-8669) administered intravenously daily for 5 days every 2 weeks to patients with advanced malignancies.
J. Clin. Oncol., Jan;26(3):361-7 (2008)